top of page

54 million Americans suffer from obstructive sleep apnea (OSA) every night.

2x

Risk of heart attack, stroke and diabetes.

50%

Patients fail CPAP therapy.

$150 Billion

Spent yearly on untreated OSA in the US

Current treatment methods are invasive and ineffective

Introducing Somnair

The first non-invasive treatment for
OSA sufferers

Somnair is a novel non-invasive neurostimuation device that opens the airway using a proprietary therapy delivery system. 

Patent Pending

nerve.png

Neurostimulation Therapy

Picture3.png

Non-Invasive

Picture2.png

Deployed at Home

bottom of page